Top

Reactions Weekly

Published in:

01-08-2023 | Ramucirumab | Case report

Docetaxel/ramucirumab

Various toxicities: 5 case reports

Published in: Reactions Weekly | Issue 1/2023

Excerpt

Author Information

An event is serious (based on the ICH definition) when the patient outcome is&colon;

* death
* life-threatening
* hospitalisation
* disability
* congenital anomaly
* other medically important event

…

Chen Y, et al. Safety and effectiveness of ramucirumab and docetaxel: a single-arm, prospective, multicenter, non-interventional, observational, post-marketing safety study of NSCLC in Japan. Expert Opinion on Drug Safety 21 : 691-698, No. 5, Jan 2022. Available from: URL: https://www.tandfonline.com/loi/ieds20

Title: Docetaxel/ramucirumab
Various toxicities: 5 case reports
Publication date: 01-08-2023
Publisher: Springer International Publishing
Keywords: Ramucirumab
NSCLC
NSCLC
Pulmonary Hemorrhage
Acute Respiratory Distress-Syndrome
Duodenal Ulcer
Idiopathic Pulmonary Fibrosis
Pneumonia
Published in: Reactions Weekly / Issue 1/2023
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-023-44288-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Docetaxel/ramucirumab

Various toxicities: 5 case reports

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2023

Nirmatrelvir+ritonavir/tacrolimus interaction

Immunosuppressants

Ciclosporin

Bosentan

Loxoprofen

Multiple drugs